Listeria. Who Benefits?

Listeria never has shown up in vegetables or fruit. Now Cantaloupe. Now Lettuce.

Who Benefit?

Drug Makers.

Food as a Weapon Government agencies.

The Centers for Disease Control and Prevention said Wednesday that 116 people have been sickened in the outbreak, including those who died.
The number of deaths has now surpassed a 1998 outbreak of listeria in processed meats that was linked to 21 deaths. A 1985 listeria outbreak in Mexican-style soft cheeses killed 52 people.

The outbreak has been linked to Rocky Ford-brand cantaloupes sold by Jensen Farms near Holly, Colo. The cantaloupes were recalled Sept. 14.

The first illnesses began after July 31.

Symptoms of listeriosis can take up to two months to develop in someone who has eaten contaminated food, so illnesses could continue to show up into November, the CDC said.

The FDA and CDC have had teams in Jensen Farms fields and packing sheds, testing the soil, water and surfaces for clues.

In the past, listeria has been most strongly linked to deli meats and soft cheeses, not produce.



Listeria bacteria grow in moist, muddy conditions and live in the guts of animals, which can transport them into fields. When humans are infected with the bacteria, they develop listeriosis, which is a rare but dangerous illness that kills approximately 30% of its victims.

It can send up to 90% of elderly people who get it to the hospital.

It is especially dangerous for pregnant women, in whom it can cause a mild illness, but it can also result in stillbirths or miscarriages.

One Drug company would benefit.

Phase I/II trial results have shown that the live Listeria cancer vaccine, Lovaxin C, is safe for humans.

In addition, three women in the cervical cancer trial had approximately 20 percent tumor reductions, researchers report.

“We are using Listeria to deliver tumor-specific antigens to the immune system in a manner that results in maximal immune and tumor-clearing response,” said John Rothman, Ph.D., vice president of clinical development at Advaxis, which is developing Lovaxin C.

“We bioengineer Listeria both to attenuate it and to cause it to secrete a tumor-specific antigen fused to a listerial protein, which makes it more effective than Listeria that just secretes the tumor antigen,” Rothman said. “By doing this we focus a very strong immune attack against the antigen in question, which is typically specific to a tumor.”

“What we’re doing is taking a lot of evolution that enabled Listeria to infect human immune systems, and an equal amount of evolution that enables humans to get rid of Listeria once this occurs. We are then co-opting and redirecting all of these complex immune responses and targeting them against cancer,” Rothman said.

A post on a stock site had this….
“The Department of Homeland Security Science and Technology Directorate and Advaxis will sign a CRADA in which an oral dosage of Listeria will be explored to treat US cattle food stock”

Advaxis granted pre-IND meeting with FDA next month

Biotreats are even watched..

Biological Threats & Epidemics
Infectious disease outbreaks, whether naturally occurring or intentionally designed, represent threats to human health and national security. Our work identifies priorities and strategies to prepare for, respond to, manage, and recover from destabilizing epidemics

Since 2001, the United States government has spent substantial resources on preparing the nation against a bioterrorist attack. Earlier articles in this series have analyzed civilian biodefense funding by the federal government for fiscal years (FY) 2001 through proposed funding for FY2011. This article updates those figures with budgeted amounts for FY2012, specifically analyzing the budgets and allocations for biodefense at the Departments of Health and Human Services, Defense, Homeland Security, Agriculture, Commerce, and State; the Environmental Protection Agency; and the National Science Foundation. This article also includes an updated assessment of the proportion of biodefense funding provided for programs that address multiple scientific, public health, healthcare, national security, and international security issues in addition to biodefense. The FY2012 federal budget for civilian biodefense totals $6.42 billion. Of that total, $5.78 billion (90%) is budgeted for programs that have both biodefense and nonbiodefense goals and applications, and $637.6 million (10%) is budgeted for programs that have objectives solely related to biodefense.

This reminds me so much of Bruce Ivins who allegedly infected people w Anthrax.

Over the summer, PBS Frontline reported that, “On July 15 … Justice Department lawyers acknowledged in court papers that the sealed area in Ivins’ lab — the so-called hot suite — did not contain the equipment needed to turn liquid anthrax into the refined powder that floated through congressional buildings and post offices in the fall of 2001.”

SO what if it was someone else?

In response to a question about the dangers posed by proliferation of labs, DHS’s current Under Secretary, Tara O’Toole said that …
“the FBI has not proven that the mailed anthrax came from USAMRIID.
She says that is “a working hypothesis.”
She says that the NAS report is the place to go to get behind the FBI’s “supposition”

The media has been harsh on Ms. O’Toole

Several months ago we warned that Tara O’Toole who recently became Under Secretary for the Science and Technology Directorate at the Department of Homeland Security would reward her friends resulting in millions of dollars in gifts to John Murtha cronies who supported her nomination.

And it now appears the Murtha/O’Toole favor factory has begun production. In February 2008, the Department of Health and Human Services (HHS) issued a request for proposal (RFP) for a second-generation Anthrax vaccine. This RFP was issued to be a re-procurement for a contract that had been canceled in 2006 for the same vaccine. And on December 7, HHS canceled the RFP.

After further review, it is becoming all too clear why this happened. Just as the year was closing and no one was paying attention, O’Toole’s friends at PharmAthene were awarded a sole-source contract, which has resulted in their stock nearly doubling. In the very same week America faced al Qaeda’s latest terrorist attack, it seems that the O’Toole-led homeland security “system worked” for PharmAthene — assuming the system is one of cronyism, political paybacks, and sole-source contracts.

This leads one to ask, who is PharmAthene, what are O’Toole’s ties, and why would the government single them out for a sole source giveaway at taxpayer expense?

PharmAthene is a company founded and run by Murtha cronies who have extremely close ties to O’Toole. In fact, O’Toole was head of the Center for Biosecurity, which is connected to the University of Pittsburgh Medical Center (UPMC), and both Murtha and O’Toole’s friends are working feverishly to position UPMC for a major biosecurity, vaccine-production contract that would result in billions flowing to Murtha’s district, and O’Toole’s private equity and lobbyist friends. According a recent report, this facility would be run by a mysterious unnamed biotechnology company. Anyone care to guess who that unnamed company is rumored to be?

PharmAthene was founded by Joel McCleary, who also happens to be a founding partner at a DC-based private equity firm, Four Seasons Ventures, and an advisor to UPMC. Partnered with McCleary at Four Seasons is none other than James Ervin, a former Murtha aide and the man one goes to for a Murtha earmark, a favor PharmAthene has benefited from in the past. Ervin lobbies for PharmAthene and Four Seasons is heavily invested.

And that’s where O’Toole comes in. In addition to running the Center for Biosecurity, O’Toole advised the Alliance for Biosecurity, which we now know PharmAthene basically runs. As the Washington Times reported, “President Obama’s nominee at the Department of Homeland Security overseeing bioterrorism defense has served as a key adviser for a lobbying group funded by the pharmaceutical industry that has asked the government to spend more money for anthrax vaccines and biodefense research.”

So this comes full circle. After doing business in the private sector, O’Toole is now in a position to continue to do business with Murtha’s people at PharmAthene, except this time, it’s with taxpayer dollars.

And it’s not as if this wasn’t a concern during her nomination hearings. As obtained by THE WEEKLY STANDARD, Senator Tom Coburn specifically asked O’Toole on June 10, “What are your views on whether the United States should fund development of a second generation anthrax vaccine? Given that Pharmathene is competing for this effort, will you recuse yourself from any role in the decision whether to support this effort?” O’Toole’s response, “I will, of course, adhere to all Executive Branch ethics requirements in consultation with the Department’s Designated Agency Ethics Official with respect to conflicts of interest. I will recuse myself from any matter in which I have a conflict of interest or the appearance of a conflict as outlined in my Ethics Agreement which has been submitted to this Committee. With regard to Pharmathene, I have, as noted above, no financial interest in the company and am not aware of any current recusal requirements.”

So O’Toole states she will not recuse herself and the favor factory begins production. Anyone concerned with this sole-source contract to O’Toole friends at PharmAthene — a wholly owned subsidiary of John Murtha, Inc. — has until January 13 to voice concerns in an effort to keep it from becoming finalized.

The alliance has spent more than $500,000 lobbying Congress and federal agencies — including Homeland Security — since 2005, congressional records show.

The University of Pittsburgh Medical Center’s Center for Biosecurity, formerly headed by Dept. of Homeland Security Undersecretary for Science & Technology Tara O’Toole, has split itself off from a special interest lobby/industry group to which it had been joined at the hip for most of the war on terror — the Alliance for Biosecurity.

“I am writing to let you know that the Center for Biosecurity at UPMC has resigned its membership in the Alliance for Biosecurity,” wrote Thomas Inglesby, its director

So in summary.
Listeria never occurred in fruit.
Biocompanies and university benefit from more spending.
And cuts in Biofood Warfare.
I remember someone saying Bruce Ivins did the anthrax because he wanted more vaccine funding.
Then Issa is asking the FBI about weapon #1 in the Fast and Furious scandal.
Bizzarre correlation or not?

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s